Single dose of mesoblast's allogeneic cell therapy provides durable pain reduction for at least three years in patients with degenerative disc disease

36-month results of phase 3 trial in chronic low back pain presented at 2022 biotech showcase 36-month results of phase 3 trial in chronic low back pain presented at 2022 biotech showcase

MESO Ratings Summary

MESO Quant Ranking